Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE

European Heart Journal

Volumn 23, Issue 4, 2002, Pages 308-314

  Antman, E M ^a   Cohen, M ^b   McCabe, C ^a   Goodman, S G ^d   Murphy, S A ^c   Braunwald, E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^c HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antithrombin; Enoxaparin; Low molecular weight heparin; Meta analysis

Indexed keywords

ANTITHROMBIN; ENOXAPARIN; HEPARIN; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ENOXAPARIN; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; STATISTICS; TIME FACTORS;

EID: 0036487098     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2779     Document Type: Article

References (30)

1. Barrowcliffe T, Johnson E, Thomas D. Low Molecular Weight Heparin. Chicester: John Wiley & Sons, 1992: 209.
2. Bounameaux H. Low-Molecular-Weight Heparins in Prophylaxis and Therapy of Thromboembolic Disease. New York: Marcel Dekker, Inc, 1994: 323.
3. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-98.
4. Antman EM, Cohen M, Radley D et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE metaanalysis, Circulation 1999; 100: 1602-8.
5. Goodman SG, Cohen M, Bigonzi F et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: 1-Year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol 2000; 36: 693-8.
6. Antman EM, Cohen M, Bernink PJLM et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. J Am Med Assoc 2000; 284: 835-42.
7. Antman EM, McCabe CH, Gurfinkel EP et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100: 1593-601.
8. Cohen M, Demers C, Gurfinkel EP et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-52.
9. Bozovich GE, Gurfinkel EP, Antman EM et al. Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time. Am Heart J 2000; 140: 637-42.
10. Antman EM. Enoxaparin: A new standard of care. Eur Heart J 2000; 2 (Suppl F): F7-F11.
11. Morrow DA, Antman EM, Tanasijevic M et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: A TIMI-11B substudy. J Am Coll Cardiol 2000; 36: 1812-7.
12. Goodman SG, Barr A, Sobtchouk A et al. Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: The Canadian ESSENCE ST segment monitoring substudy. J Am Coll Cardiol 2000; 36: 1507-13.
13. Mark DB, Cowper PA, Berkowitz SD et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: Results from the ESSENCE randomized trial. Circulation 1998; 97: 1702-7.
14. O'Brien BJ, Willan A, Blackhouse G et al. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? Am Heart J 2000; 139: 423-9.
15. Theroux P, Waters D, Lam J et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992; 327: 141-5.
16. Mombelli G, Marchetti O, Haeberli A et al. Effect of intravenous heparin infusion on thrombin-antithrombin complex and fibrinopeptide A in unstable angina. Am Heart J 1998; 136: 1106-13.
17. Lane DA, Denton J, Flynn AM et al. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218: 725-32.
18. Abildgaard U, Lindahl AK, Sandset PM. Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. Haemostasis 1991; 21: 254-7.
19. Hoppensteadt DA, Jeske W, Fareed J et al. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinolysis 1995; 6 (Suppl 1): S57-64.
20. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998; 97: 251-6.
21. Montalescot G, Philippe F, Ankri A et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: Beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation 1998; 98: 294-9.
22. Antman EM, Handin R. Low-molecular-weight heparins: An intriguing new twist with profound implications. Circulation 1998; 98: 287-9.
23. Brieger D, Dawes J. Long-term persistence of biological activity following administration of Enoxaparin sodium (clexane) is due to sequestration of antithrombin-binding low molecular weight fragments - Comparison with unfractionated heparin. Thromb Haemost 1996; 75: 740-6.
24. Lindhout T, Hemker H. Anticoagulant mechanism of action of low molecular weight heparins. In: Doutremepuich C. ed. Low Molecular Weight Heparins in Clinical Practice. New York: Marcel Dekker, Inc, 1992: 23-50.
25. Agnelli G. Pharmacological activities of heparin chains: Should our past knowledge be revised? Haemostasis 1996; 26: 2-9.
26. Montalescot G, Collet JP, Lison L et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000; 36: 110-4.
27. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis. J Am Med Assoc 1999; 282: 2058-67.
28. FRISC II Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 701-7.
29. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation: A randomised trial. Lancet 1999; 353: 429-38.
30. Kereiakes DJ, Grines C, Fry E et al. Combination enoxaparin and abciximab during percutaneous coronary intervention: A new standard of care? Curr Intervent Cardiol Rep 2000; 2: 157-64.